Key result
Oral converting enzyme inhibitor (SQ 14225) significantly reduced mean arterial pressure from 149 to 127 mmHg (P<0.02) by decreasing total peripheral resistance without changing cardiac index.
Why the study?
Does the oral converting enzyme inhibitor SQ 14225 improve haemodynamics in patients with severe essential or renovascular hypertension?
Population
8 patients with severe essential or renovascular hypertension
Design
Case_series
Authors
Loading...
May support oral ACE inhibition in severe hypertension without compromising cardiac output; case report leaves open confirmation in randomized trials.
Observational (n=8)
Does the oral converting enzyme inhibitor SQ 14225 improve haemodynamics in patients with severe essential or renovascular hypertension?
Absolute Event Rate: 127% vs 149%
p-value: p=<0.02
The oral converting enzyme inhibitor SQ 14225 effectively lowers blood pressure by reducing peripheral resistance without compromising cardiac index, with effects enhanced by sodium restriction.
Cody et al. (1978) conducted an observational in severe essential or renovascular hypertension (n=8). oral converting enzyme inhibitor (SQ 14225) vs. baseline was evaluated on Mean arterial pressure (p=<0.02). Oral converting enzyme inhibitor (SQ 14225) significantly reduced mean arterial pressure from 149 to 127 mmHg (P<0.02) by decreasing total peripheral resistance without changing cardiac index.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: